# MindMap: Quantum ML Biomarker API for Pharma Trial Cohort Targeting

**Individual Report — Pharma Vertical**
IE Business School | IMBA 25J | Frontier Technologies
Group 4 — MindMap: Behavioral Intelligence Infrastructure

---

## The Problem: $3 Billion Per Drug, 90% Failure Rate

The pharmaceutical industry spends approximately $3 billion to bring a single drug to market. Ninety percent of clinical trials fail (NIH/PMC, 2022). The dominant cause of failure is not bad science — it is the wrong patients.

Drugs that work in Phase I fail in Phase II and Phase III because the patient populations recruited into trials do not reflect the populations in which the drug produces its strongest effect. By the time this becomes clear, hundreds of millions of dollars and years of development time have been spent. The molecule worked. The cohort selection failed.

This is not a chemistry problem. It is a data problem. And it is a data problem that has gone unsolved because the industry has been looking for the answer in the wrong place — in historical clinical records that tell you who was sick, not in real-time behavioral signals that tell you who is about to present.

---

## The Insight: Behavior Precedes Biology

Humans search before they present. They describe symptoms before a GP records a diagnosis. They seek information about side effects, treatment options, and disease experiences weeks or months before they enter a clinical pathway.

Ginsberg et al. (2009) demonstrated this with influenza: Google Trends signals achieved a 0.97 correlation with CDC surveillance data with a 1–2 week predictive lead time. The behavioral signal preceded the clinical record.

This principle generalises. It is particularly powerful in CNS (central nervous system) disorders, autoimmune conditions, and chronic metabolic diseases — exactly the areas where clinical trial failure rates are highest, where patient heterogeneity is greatest, and where the gap between behavioral onset and clinical presentation is longest.

The question MindMap answers is: **which patients, right now, are exhibiting the behavioral signal clusters that predict treatment response — before they enter the clinical system?**

---

## The Opportunity: $75 Billion Market, No Behavioral Platform

The global clinical trials market is worth $75 billion annually. IQVIA.ai is the dominant analytics platform in this space — but it serves large pharma only, it is built on historical claims data, and it has no real-time behavioral signal layer.

No platform currently exists that:
1. Ingests real-time population-level behavioral signals
2. Maps them to validated clinical biomarkers
3. Produces probability-weighted cohort targeting scores
4. Operates at the scale required for multi-country trials

MindMap builds this platform. The Quantum ML Biomarker API is the pharma vertical product.

---

## The Product: Quantum ML Biomarker API

The Quantum ML Biomarker API is a licensable classification engine for pharma trial sponsors. It takes as input the behavioral signal clusters produced by MindMap's Layer 1 (data ingestion) and Layer 2 (neural mapping), runs quantum ML combinatorial inference in Layer 3, and outputs probability-weighted cohort targeting scores.

### What It Does

**Input:**
- Population-level behavioral signal clusters (search trends, symptom-related query patterns, treatment-seeking behaviors) from MindMap's behavioral data pipeline
- Trial indication specification from pharma sponsor (disease area, target patient profile, inclusion/exclusion criteria)
- Geographic scope (country, region — matched to planned trial sites)

**Processing (Layer 3 — Quantum ML Engine):**
- Quantum combinatorial inference over all behavioral signal combinations associated with the target indication
- Identification of signal clusters predictive of treatment response vs. confounded by comorbidity or care-seeking behaviour
- Cross-referenced against validated biomarker literature (PubMed integration from Layer 2)

**Output:**
- Geographic heat maps: where are the highest-probability patient populations located right now?
- Temporal scoring: which patient populations are in the signal window that predicts trial eligibility and response?
- Cohort probability scores: ranked patient population segments by predicted response probability
- Trial site recommendation: which trial sites are in catchment areas with the highest behavioral signal concentration?

### API Integration Model

The Quantum ML Biomarker API is delivered as a REST API integrated into the pharma sponsor's trial management platform (e.g., Medidata, Veeva Vault Clinical). It does not replace existing trial management systems — it layers the one capability they do not have: **forward-looking behavioral prediction before recruitment begins.**

---

## Why Quantum ML — Not Classical ML

Classical ML models for trial cohort targeting already exist. IQVIA uses them. Medidata uses them. They work well for large, homogeneous patient populations where historical patterns are predictive.

They fail precisely where the unmet need is greatest: CNS disorders, rare diseases, autoimmune conditions, and novel mechanisms of action. These are the areas where:
- Patient heterogeneity is highest (one label, many biological subtypes)
- Historical data is thinnest (small prior trial populations)
- Behavioral signals are richest (patients are most active in seeking information before presenting)

Quantum ML holds the full combinatorial interaction space open. It evaluates how behavioral signals interact across dimensions — not just which signals are present, but which *combinations* of signals, at which *intensities*, in which *temporal sequences*, in which *geographic contexts*, are predictive of treatment response.

This is not a marginal improvement. It is a different inference architecture for a different class of problem.

---

## Target Partners

### H1—H2 Pilot Partners (2026–2027)

**CNS Biotech Companies**
- Rationale: Highest trial failure rates; greatest patient heterogeneity; richest behavioral signal profiles pre-presentation
- Target profile: Mid-size CNS biotechs running Phase II trials in depression, anxiety, neurodegeneration, and pain
- Entry: 90-day behavioral signal study — does MindMap's signal output predict enrollment difficulty and dropout risk?

**Roche**
- Rationale: Global trial infrastructure; strong interest in AI-driven patient stratification; existing investment in biomarker platforms
- Entry: Partnership on oncology or CNS indication where behavioral signal layer adds value to existing stratification models

**J&J / Pfizer (H2)**
- Large pharma entry once CNS biotech pilots have produced published results
- Commercial scale: licensing the API into enterprise trial management systems

---

## The Validation Engine Role

Within the MindMap platform strategy, pharma is the **Validation Engine** — not the commercial anchor (that is insurance) and not the scale play (that is public health).

Pharmacy's role in the MindMap sequence is to **publish the proof.** Once a pharma pilot demonstrates that MindMap's behavioral signal layer predicts trial success probabilities with measurable accuracy, that published result:

1. Validates the behavioral signal thesis across an independent vertical
2. Creates the scientific credibility that makes insurance clients deepen their commitment
3. Opens the public health vertical by demonstrating the platform works at population scale

The pharma pilot results being published publicly is a deliberate strategic choice — it turns a private commercial agreement into a public proof point that accelerates all three verticals simultaneously.

---

## Implementation: Three Horizons

### H1 (Now — mid-2026): Pilot Design & Signal Validation
- Define behavioral signal taxonomy for 2–3 target CNS/oncology indications
- Run 90-day behavioral signal study against historical trial enrollment and dropout data
- Validate that behavioral signal clusters correlate with trial outcome metrics
- Engage 1 CNS biotech pilot partner
- Deliverable: Pilot study design and baseline signal correlation results

### H2 (2026–2027): API Build & Live Trials
- Build and deploy Quantum ML Biomarker API (quantum-inspired on classical infrastructure in H1; IBM Quantum enterprise access for H2 scale)
- Run API in 3 live pharma trials
- Collect outcome data: did API-targeted cohorts enroll faster, drop out less, show higher response rates?
- Submit results for peer review publication
- Deliverable: Published validation study; 3 active pharma licensing agreements

### H3 (2028–2030): Scale & Standard
- Expand to 10+ pharma clients across CNS, oncology, autoimmune, rare disease
- Full Google Willow quantum inference for large-scale multi-country trials
- API becomes standard integration for clinical trial management platforms
- Deliverable: Quantum ML Biomarker API as industry standard for behavioral cohort targeting

---

## Cybersecurity: Why It Is the Commercial Prerequisite Here Too

Pharma trial data is among the most commercially sensitive data in the world. A breach of trial cohort data, biomarker models, or indication strategies is a catastrophic competitive event for a pharma sponsor.

MindMap's Layer 4 (Post-Quantum Security & Governance) is the reason pharma will sign the data sharing agreement:
- NIST FIPS 203/204/205 post-quantum encryption on all data in transit and at rest
- Zero-trust architecture: no standing access to trial data; task-scoped, time-limited permissions only
- Differential privacy: mathematical guarantee against individual patient re-identification
- Regulatory audit trail: GDPR, HIPAA, and EU AI Act compliance built into platform operations

Without this layer, no pharma legal team approves the contract. With it, MindMap removes the single largest barrier to pharma partnership.

---

## The Competitive Gap

| Capability | MindMap | IQVIA.ai | Medidata AI | Veeva |
|---|---|---|---|---|
| Real-time behavioral signals | ✅ | ❌ | ❌ | ❌ |
| Quantum ML cohort targeting | ✅ | ❌ | ❌ | ❌ |
| Multi-vertical platform | ✅ | ❌ | ❌ | ❌ |
| Post-quantum security | ✅ | ❌ | ❌ | ❌ |
| Available to mid-size biotechs | ✅ | ❌ (large pharma only) | ⚠️ | ⚠️ |

IQVIA.ai is the most direct competitor. It is large-pharma-only, historically oriented, and has no behavioral signal layer. MindMap targets the gap it leaves open: mid-size biotechs running CNS and rare disease trials where the unmet need is highest and the incumbent cannot serve them.

---

## Sources

- Ginsberg, J. et al. (2009). Detecting influenza epidemics using search engine query data. *Nature*, 457, 1012–1014.
- NIH/PMC (2022). Clinical trial failure rates and root causes.
- NIST (2024). FIPS 203, FIPS 204, FIPS 205 — Post-Quantum Cryptographic Standards.
- Google Quantum AI (December 2024). Google Willow: 105-qubit quantum chip announcement.
- IQVIA (2025). Global clinical trials market sizing.

---

*Individual report — Pharma Vertical. Part of the MindMap: Behavioral Intelligence Infrastructure group project. See `platform-architecture/mindmap-overview.md` for full platform context and `individual/insurance/board-memo.md` for the insurance vertical individual report.*
